IN2012DN05099A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05099A
IN2012DN05099A IN5099DEN2012A IN2012DN05099A IN 2012DN05099 A IN2012DN05099 A IN 2012DN05099A IN 5099DEN2012 A IN5099DEN2012 A IN 5099DEN2012A IN 2012DN05099 A IN2012DN05099 A IN 2012DN05099A
Authority
IN
India
Prior art keywords
active agents
delivery compositions
conjugated
charge
polymer
Prior art date
Application number
Other languages
English (en)
Inventor
Omid C Farokhzad
Nagesh Kilishetti
Shanta Dhar
Stephen J Lippard
Robert S Langer
Pedro M Valencia
Original Assignee
Brigham & Womens Hospital
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Massachusetts Inst Technology filed Critical Brigham & Womens Hospital
Publication of IN2012DN05099A publication Critical patent/IN2012DN05099A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN5099DEN2012 2009-12-16 2010-12-16 IN2012DN05099A (forum.php)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28718809P 2009-12-16 2009-12-16
PCT/US2010/060814 WO2011084620A2 (en) 2009-12-16 2010-12-16 Particles for multiple agent delivery

Publications (1)

Publication Number Publication Date
IN2012DN05099A true IN2012DN05099A (forum.php) 2015-10-09

Family

ID=44306061

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5099DEN2012 IN2012DN05099A (forum.php) 2009-12-16 2010-12-16

Country Status (7)

Country Link
US (1) US20130017265A1 (forum.php)
EP (1) EP2512522A4 (forum.php)
JP (1) JP2013514977A (forum.php)
CN (1) CN102791294A (forum.php)
EA (1) EA201290506A1 (forum.php)
IN (1) IN2012DN05099A (forum.php)
WO (1) WO2011084620A2 (forum.php)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3223013T3 (pl) 2009-07-02 2019-07-31 Sloan-Kettering Institute For Cancer Research Fluorescencyjne nanocząstki na bazie krzemionki
US12161734B2 (en) 2009-07-02 2024-12-10 Sloan-Kettering Institute For Cancer Research Multimodal silica-based nanoparticles
EP2542057A4 (en) * 2010-03-02 2014-10-15 Vindico Nanobio Technology Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFAMOUS DISEASES
EP2600901B1 (en) 2010-08-06 2019-03-27 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2750662A4 (en) 2011-08-31 2015-06-24 Univ Georgia NANOPARTICLES OBTAINING APOPTOSIS
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
US9526701B2 (en) 2011-12-20 2016-12-27 Keith R. Latham Sustained drug release and improved product stability using non-covalent particle coating methods
US9011832B2 (en) 2012-02-09 2015-04-21 Novus International, Inc. Heteroatom containing cyclic dimers
US10416167B2 (en) 2012-02-17 2019-09-17 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151670A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
ES2703051T3 (es) 2012-07-12 2019-03-06 Novus Int Inc Composiciones de matriz y de capa para la protección de agentes bioactivos
JP2014051478A (ja) * 2012-09-10 2014-03-20 Panasonic Corp 機能性物質、生体活性用薬剤及び機能性物質の生体内への浸透方法、並びに機能性物質放散装置及び空気清浄装置
WO2014059022A1 (en) 2012-10-09 2014-04-17 The Brigham And Women's Hospital, Inc. Nanoparticles for targeted delivery of multiple therapeutic agents and methods of use
US20160279263A1 (en) * 2012-11-14 2016-09-29 Cornell University Drug delivery compositions and methods targeting p-glycoprotein
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
AU2014232907B2 (en) 2013-03-15 2017-12-21 Cornell University Multimodal silica-based nanoparticles
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20170000740A9 (en) * 2013-04-09 2017-01-05 University Of Georgia Research Foundation Inc. Combination therapeutic nanoparticles
EP3003343B1 (en) 2013-06-07 2019-10-23 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
EP3016715A4 (en) 2013-07-01 2017-02-08 University Of Georgia Research Foundation, Inc. Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
JP2016525549A (ja) * 2013-07-26 2016-08-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療物質を含有するポリマー粒子を製造するための方法およびデバイス
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
CN105980401A (zh) 2013-10-03 2016-09-28 现代治疗公司 编码低密度脂蛋白受体的多核苷酸
WO2015089389A1 (en) * 2013-12-12 2015-06-18 University Of Georgia Research Foundation, Inc. Prodrug for release of cisplatin and cyclooxygenase inhibitor
AU2014373656B2 (en) 2013-12-31 2019-12-05 Cornell University Systems, methods, and apparatus for multichannel imaging of fluorescent sources in real time
WO2015138992A1 (en) 2014-03-14 2015-09-17 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
JP2017516755A (ja) * 2014-04-08 2017-06-22 ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド ミトコンドリア標的化白金（ｉｖ）プロドラッグ
CN106659797B (zh) * 2014-05-29 2021-04-27 纪念斯隆-凯特琳癌症中心 纳米粒子药物结合物
WO2016054522A1 (en) 2014-10-03 2016-04-07 Ntercept, Llc Compositions and methods for inhibiting the biological activity of soluble biomolecules
AU2016271040A1 (en) 2015-05-29 2017-11-23 Cornell University Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
CN116854745A (zh) * 2015-06-25 2023-10-10 新纳特产品公司 药物共晶组合物及其用途
AU2016305473B2 (en) * 2015-08-13 2021-08-19 Dana-Farber Cancer Institute, Inc. Biomaterials for combined radiotherapy and immunotherapy of cancer
EP3377113A4 (en) * 2015-11-18 2019-06-19 Synergy Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF TREATMENT AND DETECTION OF CANCER
AU2016377775A1 (en) * 2015-12-23 2018-07-12 Dana-Farber Cancer Institute, Inc. Immune cell-targeted particles
WO2017184586A1 (en) 2016-04-18 2017-10-26 The Trustees Of Columbia University In The City Of New York Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
WO2018129207A1 (en) * 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
JP2020520953A (ja) 2017-05-25 2020-07-16 メモリアル スローン ケタリング キャンサー センター ジルコニウム−８９で標識した超小型ナノ粒子およびその方法
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions
EP4359026A4 (en) * 2021-06-21 2025-05-21 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Compositions, methods and devices for the delayed release of an active substance
CN114259573B (zh) * 2022-01-06 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种含有胆碱酯酶重活化剂的脑靶向脂质体及其制备方法和用途
CN115382476B (zh) * 2022-07-26 2024-10-22 华东师范大学 一种超小粒径聚合物纳米颗粒的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
CA2187353C (en) * 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6482439B2 (en) * 1999-12-29 2002-11-19 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
AU2001284982A1 (en) * 2000-08-15 2002-02-25 Board Of Trustees Of The University Of Illinois Method of forming microparticles
WO2002026241A1 (fr) * 2000-09-26 2002-04-04 Center For Advanced Science And Technology Incubation, Ltd. Micelle polymere renfermant du cisplatine et utilisation
US20040047835A1 (en) * 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7371781B2 (en) * 2003-09-22 2008-05-13 University Of Utah Research Foundation Tumor environment-induced ligand-expressing nanocarrier system
AU2003272127A1 (en) * 2003-10-24 2005-05-11 Samyang Corporation Polymeric composition for drug delivery
BRPI0510477B1 (pt) * 2004-04-28 2023-01-17 Angiotech Biomaterials Corporation Método para formar um gel e dispositivo para uso em aplicações médicas
AU2005269800B8 (en) * 2004-07-19 2011-12-01 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
IL178645A0 (en) * 2006-10-16 2007-02-11 Ariel University Res And Dev C Dendrimeric platform for controlled release of drugs
EP2132133A4 (en) * 2007-03-02 2013-04-17 Univ Illinois RELEASE OF PARTICULATE ACTIVE SUBSTANCES
CN101707869A (zh) * 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物

Also Published As

Publication number Publication date
EA201290506A1 (ru) 2013-03-29
WO2011084620A3 (en) 2011-11-17
US20130017265A1 (en) 2013-01-17
EP2512522A4 (en) 2013-09-25
CN102791294A (zh) 2012-11-21
EP2512522A2 (en) 2012-10-24
JP2013514977A (ja) 2013-05-02
WO2011084620A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
IN2012DN05099A (forum.php)
GT201200332A (es) Composiciones sòlidas
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
MX2014011815A (es) Composiciones farmaceuticas de liberacion inmediata con propiedades disuasivas de abuso.
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
CO6640208A2 (es) Composiciones solidas
AU2019268096A1 (en) Pharmaceutical compositions comprising modified fucans for use in the treatment of fibrous adhesions and other disorders
MY154909A (en) Novel thiophene derivatives
GEP20156230B (en) Forms of rifaximin and usage thereof
TN2012000195A1 (en) Solid dispersion of rifaximin
AR081678A1 (es) Metodos y composiciones para administracion intratecal de arisulfatasa a
MX341200B (es) Composicion farmaceutica de disolucion rapida.
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
MX2013002422A (es) Sales de lorcaserina con acidos opticamente activos.
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
UA102432C2 (ru) Цитотоксичные конъюгаты с соединением, которое связывает рецептор нейропептиду y
TW200942530A (en) Pyridine compounds
TW200942524A (en) Novel aminomethyl benzene derivatives
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
WO2010009140A3 (en) Methods, systems and devices for administration of chlorine dioxide
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
HK1200695A1 (en) Optimised subcutaneous therapeutic agents
WO2011126839A3 (en) Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
HK1204962A1 (en) Cyclodextrin-based polymers for therapeutic delivery